Journal Scans
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Woman’s Health Initiative Postintervention Analysis and Cancer Incidence
G Heiss, R Wallace, GL Anderson, A Aragaki, SAA Beresford, R Brzyski, RT Chlebowski, M Gass, A LaCroix, JE Manson, RL Prentice, J Rossouw, ML Stefanick, for the WHI Investigators
Yes
20080205
2008 Mar 5
JAMA
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
JAMA. 2008 Mar 5;299(9):1036-1045, G Heiss, R Wallace, GL Anderson, A Aragaki, SAA Beresford, R Brzyski, RT Chlebowski, M Gass, A LaCroix, JE Manson, RL Prentice, J Rossouw, ML Stefanick, for the WHI Investigators
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
CONTEXT: The Women's Health Initiative (WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits. OBJECTIVE: To report health outcomes at 3 years (mean 2.4 years of follow-up) after the intervention was stopped. DESIGN, SETTING, AND PARTICIPANTS: The intervention phase was a double-blind, placebo-controlled, randomized trial of conjugated equine estrogens (CEE) 0.625 mg daily...
